Investor Growth Capital Limited

Total investments

147

Average round size

22M

Portfolio companies

83

Rounds per year

1.37

Lead investments

39

Follow on index

0.44

Exits

59

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyInternetSoftwareAnalyticsInformation TechnologyHealth CareEnterprise SoftwareManufacturingMedical DeviceMedical

Summary

In 1916 was created Investor Growth Capital Limited, which is appeared as VC. The leading representative office of defined VC is situated in the Stockholm. The company was established in Europe in Sweden.

We also calculated 9 valuable employees in our database.

When the investment is from Investor Growth Capital Limited the average startup value is 100-500 millions dollars. Considering the real fund results, this VC is 14 percentage points more often commits exit comparing to other organizations. Opposing the other organizations, this Investor Growth Capital Limited works on 6 percentage points more the average amount of lead investments. The top activity for fund was in 2006. The increased amount of exits for fund were in 2016. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 7-12 deals every year.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. We can highlight the next thriving fund investment areas, such as Biotechnology, Enterprise Software. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ChinaCache, BlueArc, Acquia.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Investor Growth Capital Limited, startups are often financed by Three Arch Partners, Sigma Partners, InterWest Partners. The meaningful sponsors for the fund in investment in the same round are Venrock, Three Arch Partners, Thomas, McNerney & Partners. In the next rounds fund is usually obtained by Versant Ventures, Three Arch Partners, InterWest Partners.

Show more

Investments analytics

Analytics

Total investments
147
Lead investments
39
Exits
59
Rounds per year
1.37
Follow on index
0.44
Investments by industry
  • Health Care (42)
  • Software (35)
  • Medical Device (32)
  • Medical (30)
  • Biotechnology (27)
  • Show 115 more
Investments by region
  • United States (130)
  • China (4)
  • Sweden (7)
  • Switzerland (2)
  • Israel (1)
  • Show 2 more
Peak activity year
2006
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
22
Avg. valuation at time of investment
55M
Group Appearance index
0.93
Avg. company exit year
13
Avg. multiplicator
0.82
Strategy success index
0.30

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Synosia Therapeutics 12 Oct 2010 Biotechnology, Drug Discovery, Pharmaceuticals, Medical, Therapeutics Late Stage Venture 30M Switzerland, Basel-City, Basel
Transcend Medical 17 Jan 2012 Health Care, Medical Device, Medical Early Stage Venture 16M United States, California

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.